financetom
Business
financetom
/
Business
/
Canada's Rogers profit takes hit from higher costs related to Shaw acquisition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canada's Rogers profit takes hit from higher costs related to Shaw acquisition
Apr 24, 2024 5:45 PM

April 24 (Reuters) - Rogers Communications ( RCIAF )

posted a drop in first-quarter profit on Wednesday, hurt by

higher costs from the acquisition of Shaw Communications,

sending shares of the Canadian telecom company down more than

3%.

The company saw a 23% jump in operating expenses in the

quarter, as it booked C$142 million ($103.6 million) in

restructuring costs mainly for severance, including about C$30

million for its acquisition of Shaw Communications. The C$20

billion deal closed last year.

"Finance costs, the acquisition of Shaw Telecom, and

lower media subscription revenues are all weighing on net

earnings," said Michael Ashley Schulman, chief investment

officer at Running Point Capital.

Net income fell 50% to C$256 million. However, adjusted

profit was in line with expectations. The net income drop took

the shine off strong growth in Rogers' wireless business.

The company added 98,000 net monthly bill-paying wireless

phone subscribers in the quarter, topping the Visible Alpha

consensus estimate of 77,530 net additions, helped by demand

from rising population driven by temporary foreign workers and

immigrants.

Revenue for the company's media business, which owns the

Toronto Blue Jays baseball team, fell 5% to C$479 million in the

quarter ended March 31 due to lower subscriber revenue and

higher media content costs. The business also saw a 7% rise in

operating costs to C$582 million because of programming and

production costs and higher payroll-related expenses for its

baseball team.

In the quarter, Rogers' free cash flow, a metric closely

watched by investors as it helps determine dividend payouts,

rose 58% from a year earlier to C$586 million, beating a Visible

Alpha estimate of C$501.8 million.

The company's total revenue rose about 28% to C$4.90

billion, compared with analysts' average estimate of C$4.92

billion, according to 12 analysts polled by LSEG data.

($1 = 1.3683 Canadian dollars)

($1 = 1.3702 Canadian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Salesforce to invest $15 billion in San Francisco over five years
Salesforce to invest $15 billion in San Francisco over five years
Oct 13, 2025
Oct 13 (Reuters) - Salesforce ( CRM ) said on Monday it will invest $15 billion in San Francisco over the next five years to support artificial intelligence innovation and workforce development in the city. ...
Central Bancompany Files for IPO
Central Bancompany Files for IPO
Oct 13, 2025
09:05 AM EDT, 10/13/2025 (MT Newswires) -- Central Bancompany (CBC) said Monday that it has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of its class A common stock. The company said that the size and pricing of the proposed offering have not yet been decided. Central Bancompany said it has applied...
Citadel to acquire leading German power trader FlexPower
Citadel to acquire leading German power trader FlexPower
Oct 13, 2025
BERLIN, Oct 13 (Reuters) - Investment firm Citadel said on Monday that it had agreed to acquire 100% of Hamburg-based power trading firm FlexPower ( FLXP ). The move comes after Miami, Florida-based Citadel acquired Japanese power wholesaler Energy Grid in 2024 and built out a new trading base in Australia in 2025. Terms and value of the transaction were...
MannKind's Biologics License Application for Diabetes Treatment Afrezza Accepted by FDA
MannKind's Biologics License Application for Diabetes Treatment Afrezza Accepted by FDA
Oct 13, 2025
09:05 AM EDT, 10/13/2025 (MT Newswires) -- MannKind ( MNKD ) said Monday that the US Food and Drug Administration has accepted for review its supplemental biologics license application for Afrezza Inhalation Powder to treat children and adolescents with type 1 or type 2 diabetes. If approved, Afrezza, approved for adults age 18 and above, would be the first needle-free...
Copyright 2023-2026 - www.financetom.com All Rights Reserved